Abstract:Medulloblastoma (MB) is the most common malignant brain tumor in children. CyclinD1 is strongly implicated in the control of G1 progression and the phosphorylation of the retinoblastoma protein; p16 could specifically interact with cyclinD1 to inhibit the activity of cyclin-dependent kinase 4. The purpose of this study was to investigate whether quantitative assessment of cyclinD1 and p16 may predict the clinical prognosis in MB. We analyzed the expression of cyclinD1 and p16 antigens in a series of 42 MB with various grades and pathological types by immunohistochemical analysis on paraffin-embedded sections. Then, the correlation of cyclinD1 and p16 expression patterns with clinical-pathological features of patients and their prognostic relevance were determined. Compared with the normal cerebellum, expression of cyclinD1 in MB was significantly higher [69.05% (29/42) vs. 9.5% (4/42), P = 0.002], expression of p16 was significantly lower [42.9% (18/42) vs. 85.7% (36/42), P = 0.01]. CyclinD1 expression in MB was up-regulated in metastatic stage ( P = 0.01), pathological type ( P = 0.02), necrosis ( P = 0.009), differentiation level ( P = 0.01) as well as with differentiation direction ( P = 0.03); p16 expression in MB was down-regulated with metastatic stage ( P = 0.01), pathology type ( P = 0.02), necrosis ( P = 0.009) as well as with differentiation level ( P = 0.01); negative significant correlation between p16 immunostaining and cyclinD1 was observed in MB (rs = −0.36, P = 0.02). We also found a statistically significant relationship between the percent of cyclinD1-positive cells and p16-positive cells in the tumors and clinical outcome, with higher levels of cyclinD1 and lower levels of p16 correlating with a worse prognosis. CyclinD1 and p16 may be independent biomarkers for clinical prognosis in MB. A combined detection of cyclinD1+/p16− expression may benefit us in prediction of a poor survival of MB.

Expressions of GSK-3beta, Beta-catenin and PPAR-gamma in Medulloblastoma

Expressions of Beta-Catenin, SUFU and VEGFR-2 Proteins in Medulloblastoma

Relationship Between Expression of Beta-Catenin and VEGFs (VEGFA, VEGF-C), VEGF Receptors-2 (VEGFR-2) in Medulloblastoma

The Expression of PI 3 K , AKT , Β-Catenin and VEGFR 2 in Medulloblastoma

Expressions of PI3K, AKT and Nrf2 in Medulloblastoma and Relevant Significances

Examining the Biomarkers and Molecular Mechanisms of Medulloblastoma Based on Bioinformatics Analysis

The Expression of the EGF Receptor Family and Their Ligands in Human Medulloblastomas

High Expression of GABAA Receptor β Subunit Genes Is Associated with Longer Overall Survival in Medulloblastoma

Expression and Significance of Gsk-3β、β-catenin、CyclinD1 in Gliomas

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Expression of VEGFR-2 in Medulloblastoma of Children

Expression and Clinical Relevance of SPOPL in Medulloblastoma.

Gene Expression of Growth Signaling Pathways is Up-Regulated in CD133-positive Medulloblastoma Cells.

A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma

PATH-13. SNCA, A NOVEL MARKER FOR GROUP 4 MEDULLOBLASTOMAS

Expression and Clinical Significance of Bcl-X_l Mrna and Its Protein in Childhood Medulloblastoma

Comprehensive Analysis of a Microrna Expression Profile in Pediatric Medulloblastoma.

Screening and Identification of LMNB1 and DLGAP5, Two Key Biomarkers in Gliomas

Pathologic and clinical features of medulloblastoma:analysis of 51 cases

Cnsc-03. High Expression Of Piccolo And Syntaxin-1A In Paediatric Medulloblastoma Due To Both: High Neuronal Fraction And Endogenous Expression

Identification of Core Genes and Pathways in Medulloblastoma by Integrated Bioinformatics Analysis